SS Kodex Healthcare ETF (266420)

Overview

BIOTON S.A. is a biotechnology firm rooted in Ozarów Mazowiecki, Poland, with a global operational footprint. Established in 1989, the company has carved a niche in the biopharmaceutical industry, focusing on the development, production, and distribution of pharmaceutical ingredients and medicinal products. With a significant presence both in Poland and internationally, BIOTON S.A. is dedicated to addressing the needs of diabetic patients by offering a comprehensive range of products designed to manage and monitor this condition effectively.

Products and Services

BIOTON S.A. offers a diversified portfolio of diabetes management solutions:

• Recombinant Human Insulin: A synthetic form of insulin, produced using recombinant DNA technology, designed to help control blood glucose levels in patients with diabetes.
• Oral Diabetic Drugs: A range of medications taken orally to help manage blood sugar levels in people with type 2 diabetes.
• Strips for Measuring Sugar in Blood: Test strips used in conjunction with a blood glucose meter to monitor blood sugar levels at home.
• Gensulin N, Gensulin R, and Gensulin M30: A series of insulin formulations catering to different absorption rates and duration of action to suit the individual needs of patients. Gensulin N is designed for intermediate-acting insulin needs; Gensulin R for rapid-acting insulin response; and Gensulin M30, a premixed insulin providing both immediate and sustained insulin release.
• GensuPen 2: An automatic injection system developed for the easy and precise administration of insulin, enhancing the convenience and effectiveness of diabetes management.
• GensuCare Glucometer: A cutting-edge diabetes monitoring technology that offers accurate blood sugar readings, facilitating effective daily diabetes management.
• Needles: High-quality needles designed for ease of use and minimal discomfort, compatible with the GensuPen 2 automatic injection system.